When AMIC or MACI is worth discussing

Cartilage repair tends to be worth discussing when symptoms are coming from a focal patch of damaged cartilage (a discrete “pothole” seen on MRI or at arthroscopy), and the rest of the joint still looks reasonably preserved. By contrast, when pain and stiffness reflect more established, widespread wear with joint-space narrowing—described in the hip literature as higher degenerative grades such as Tönnis grade ≥2—joint-preserving cartilage procedures generally perform less well and the conversation often shifts towards arthritis management and, in some cases, replacement options. [1]

In the knee, AMIC (autologous matrix-induced chondrogenesis) usually sits in the “medium-sized focal defect” category—roughly 2–8 cm² in published series—typically for full-thickness (grade III–IV) chondral or osteochondral defects rather than superficial fraying. It is a single-stage operation that combines microfracture with coverage by a type I/III collagen membrane (for example, Chondro-Gide), aiming to stabilise the blood clot and support repair tissue formation. [2,3]

Expected change is typically gradual rather than immediate. A 2024 systematic review (18 studies; 490 patients) reported clinically meaningful gains in common knee function scores and about a 4-point VAS pain reduction after AMIC, while MRI-based “fill” is often substantial but not perfect. [2] A 2023 multicentre retrospective series (101 patients; defects 2–8 cm², mean 3.44 cm²) similarly reported significant improvements in SF-36, KOOS and IKDC at a mean follow-up of ~30 months, with mean MOCART score around 75%. [3]

For the hip, MACI-style cell grafts can be done, but the evidence base is much smaller than in the knee. A prospective case series of 29 patients (mean age 30.3 years; mean acetabular defect 2.21 cm²) reported improved iHOT-33, EQ-5D and Non-Arthritic Hip Score at around 19 months after a two-step, arthroscopic MACI approach. [4] A 2017 hip review positions microfracture mainly for high-grade defects <2 cm², with AMIC or MACI considered when symptomatic full-thickness defects are ≥2 cm²—highlighting that the final choice depends on defect size and grade, joint status, and overall biomechanics. [1]

Who AMIC knee surgery is for and how it compares

AMIC is a single-stage knee cartilage repair that combines microfracture (small holes made in the bone under the defect) with a type I/III collagen membrane such as Chondro-Gide. The rationale for adding the membrane is to help contain and protect the marrow clot created by microfracture, so the repair response has a more stable “scaffold” to organise within. [2,3]

Who it tends to fit

Published knee series cluster around moderate-sized focal defects, rather than tiny scuffs or widespread arthritis. Across a 101-patient multicentre study and a 2024 systematic review (18 studies; 490 patients), mean defect size sits around 3.4–3.5 cm², with inclusion ranges commonly spanning roughly 2–8 cm². These are typically full-thickness (Outerbridge/ICRS grade III–IV) chondral or osteochondral lesions in relatively young, active adults, where the rest of the joint is not showing advanced degenerative change. [2,3]

What outcomes look like at 2–3 years (numbers, then real life)

Rather than leaving the results as a list of acronyms, it helps to link the headline changes to everyday function. In the 101-patient multicentre series, patient-reported knee scores (including KOOS and IKDC) improved significantly by a mean follow-up of about 30 months, while MRI-based repair (MOCART) averaged 75%—often “good fill”, but not a perfect re-creation of native cartilage. [3] A 2024 systematic review similarly found clinically significant improvements across common knee scoring systems and reported about a 4-point reduction in VAS pain across included studies. [2]

A 2024 systematic review concluded that AMIC is generally a safe, effective and reliable option for moderate-sized knee chondral defects (often described as >2.5 cm²), with clinically meaningful improvements reported across common scoring systems. [2]

How it compares with other modern repairs

Where a two-stage cell graft (MACI) or arthroscopic minced cartilage is also on the table for similar focal knee lesions, a matched-pair 2-year study (48 patients; 16 per group) found significant pain and KOOS improvements in all three groups, without statistically significant differences between techniques at 2 years. That positions AMIC as a plausible “middle option”: less complex than cell-based approaches, but aiming to outperform microfracture alone by adding matrix support. [5]

For surgical approach, a 2023 meta-analysis across 24 studies reported broadly similar IKDC and KOOS outcomes whether AMIC was done arthroscopically or via a mini-open approach; arthroscopy showed slightly lower pain and fewer stiffness/revision complications, while open surgery tended to score higher on MOCART imaging. The overall message is that technique and access route can tweak the peri-operative course and MRI appearance, but published 2-year function is usually in the same ballpark. [6]

Takeaway: for a focal, full-thickness knee defect in the “few square centimetres” range (around 2–8 cm²) with a relatively preserved joint, AMIC commonly sits between basic marrow-stimulation and more resource-intensive cell-graft strategies, with published 2–3 year results showing meaningful average improvements—but not guarantees, and not always perfect cartilage fill on MRI. [2,3,6]

What AMIC knee recovery usually looks like

Rehabilitation after AMIC is typically a structured build over 6–12 months, rather than a quick “few weeks” recovery. The most consistent pattern in published protocols is early protection to let the repair bed settle, followed by graduated loading and a long, progressive return to impact activities; the milestone ranges below are drawn from a 2025 systematic review of AMIC rehabilitation protocols, described here by time-point rather than by internal study codes. [7]

Weeks 0–2: settling the knee

In the first 10–14 days, the focus is usually on controlling pain and swelling, keeping the quadriceps “online”, and moving the knee within the early limits set by the surgical team. For femoral condyle repairs, many protocols start with partial weightbearing on crutches during this phase, reflecting the aim of avoiding early overload while the repair response establishes. [7]

Weeks 2–6: building range and a steadier walking pattern

Between week 2 and week 6, knee flexion is commonly increased stepwise, with many condylar protocols aiming for near-full or full range of motion by about 6 weeks. Functionally, this phase often looks like longer, more confident indoor walking (still with crutches for some), and physiotherapy work that prioritises control and reducing the “swollen knee → weak thigh” cycle that can linger into week 4–6. [7]

Weeks 6–12: coming off crutches and restoring normal daily movement

Across condylar AMIC protocols in the 2025 review, progression to full weightbearing commonly happens somewhere between 4 and 10 weeks (with an average around 7–8 weeks). In day-to-day terms, the key change in this window is moving towards a normal gait without a limp and tolerating longer walks; the main limiter is often residual swelling or muscle endurance rather than sharp pain by month 2–3. [7]

Months 3–6: strength first, then impact preparation

From around 3 months, rehabilitation usually becomes more strength- and capacity-led, with low-impact conditioning (for example, gym-based cycling or pool work) commonly used as a bridge while the knee tolerates more load. In the same 2025 protocol review, light jogging was generally introduced at around 6 months, typically only once strength, movement control and clinical review were reassuring. [7]

Months 6–12 (and sometimes beyond): return to sport as a progression, not a date

In published protocols, return to sport after AMIC spans a wide range—4 to 18 months, averaging roughly 11 months—which fits the reality that “sport-ready” means more than being able to run. This stage is usually about building repeat-effort tolerance (training loads, change of direction, contact drills where relevant) rather than simply ticking off a single test at month 9–12. [7]

Condylar vs patellofemoral differences

Location can shift the timetable. For patellofemoral lesions, some protocols allow immediate full weightbearing, with unrestricted range often targeted by about 4–8 weeks, and some return-to-sport timelines reported as 4–6 months. These faster pathways are not universal, and progress can be slower when other procedures are done at the same time or where pre-operative weakness is marked. [7]

Overall, evidence comparing arthroscopic vs mini-open AMIC suggests similar functional outcomes, but slightly different early-course profiles (for example, arthroscopy showing slightly lower pain and fewer stiffness/revision complications in a 2023 meta-analysis), reinforcing why the early weeks tend to prioritise swelling control and motion quality as much as strength. [6]

Treatment options for hip cartilage defects

Hip cartilage surgery is usually framed around whether the problem is a focal, contained defect (often alongside femoroacetabular impingement in younger adults) or whether there is already established degenerative change, where joint-preserving cartilage repair tends to be less predictable. A 2017 hip review specifically flags poorer results once there is joint-space narrowing consistent with Tönnis grade ≥2, which is one reason hip replacement becomes the more realistic pathway in that setting. [1]

A commonly cited framework from that same 2017 review uses a combination of cartilage grade and defect size rather than a single “best operation for everyone”: [1]

• Lower-grade wear (grade I–II) in patients under 50: arthroscopic debridement/chondroplasty is often discussed, typically alongside addressing contributing mechanics (for example, impingement correction where relevant).
• Full-thickness lesions (grade III–IV) under 2 cm²: microfracture is commonly used as a marrow-stimulation option for small, high-grade defects.
• Full-thickness lesions (grade III–IV) at or above 2 cm²: matrix-based repairs such as AMIC or MACI are described as options in selected patients.

Once a defect sits in the ≥2 cm², grade III–IV category, the real-world discussion often turns on one-stage versus two-stage strategies, especially because the hip evidence base is thinner than the knee’s and relies largely on observational experience rather than large comparative trials. [1,4]

Within that framework, AMIC in the hip is presented as a single-stage adaptation of marrow stimulation with a collagen membrane, with practical appeal because it aims to combine microfracture biology with matrix containment in one arthroscopic sitting. [1]

Other tools mentioned in hip reviews include mosaicplasty/OATS for select focal lesions, and microfragmented adipose tissue transplantation (MATT) for patterns such as delamination or lower-grade change, alongside broader joint-preservation steps when the underlying problem is not just cartilage (for example, bony shape or coverage issues), rather than expecting a cartilage technique alone to carry the result. [1]

Two-stage MACI in the hip and how common it is

Two-stage cell grafting (MACI/ACI-style repair) has been used in the hip, but it remains a specialist option rather than routine hip arthroscopy. [1,4]

The clearest published example is a prospective case series of 29 patients with full-thickness acetabular defects (mean size 2.21 cm², ICRS 3A–3D; mean age 30.3 years) treated with an injectable MACI product delivered arthroscopically. Over a mean follow-up of about 19 months, the authors reported statistically significant improvements across hip outcome measures including iHOT-33, EQ-5D, and the Non-Arthritic Hip Score (NAHS)—supporting short-term feasibility and symptom improvement in a carefully selected, young cohort (many with femoroacetabular impingement as the underlying driver). [4]

What makes MACI different is the two-stage workflow. In broad terms it involves:

• Stage 1 arthroscopy: treat contributory pathology (commonly impingement) and take a cartilage biopsy.
• Cell expansion: chondrocytes are grown in a laboratory.
• Stage 2 procedure: the cultured cells on/within a matrix are implanted into the defect (in hip reports, this has been done arthroscopically). This staged logic is described in the hip case-series methods and is also reflected in how hip reviews position MACI against single-stage options such as AMIC. [1,4]

A key reason hip MACI is relatively uncommon is that MACI’s mainstream indication and strongest trial-backed evidence are knee-focused, whereas the hip literature is still dominated by small, non-comparative series. [2,4]

Bottom line: the best current evidence for hip MACI is small and short-term, and it is therefore usually considered for selected younger patients with focal, full-thickness defects—often when defect size moves beyond the “small microfracture” category. A 2017 hip review places MACI and AMIC as matrix-based options for symptomatic grade III–IV defects ≥2 cm², with AMIC carrying the obvious logistical advantage of being single-stage; robust head-to-head hip comparisons and long-term joint-preservation data are not yet established. [1]

Choosing a pathway and next steps

Decision-making tends to be clearest when the knee and the hip are treated as two different evidence problems. For medium-sized, focal knee defects, AMIC has a relatively consistent 2–3 year evidence base showing clinically meaningful improvements, and published rehabilitation protocols give a fairly predictable “protected early, build over months” recovery pattern. [2,7]

Hip cartilage repair is more individualised: a widely cited 2017 hip review still frames choices by grade and size (for example, microfracture under 2 cm² versus matrix-based options at ≥2 cm²), but the outcome data for hip MACI and related techniques remain limited, with published clinical evidence dominated by small series such as a 29-patient report with follow-up around 19 months. [1,4]

To avoid this ending reading like a clinic advert, the close below keeps to a practical planning checklist. In consultation, the pathway usually sits across four stages—symptom management, biologic/injection support, cartilage restoration (single-stage scaffold repairs such as AMIC versus staged cell-grafts), and joint replacement when preservation is no longer realistic—based on history, examination and imaging (defect size/grade, joint space, alignment and prior surgery). [1]

• What is the confirmed defect size (cm²) and grade (ICRS/Outerbridge)?
• Is the joint otherwise preserved (for the hip, is there any suggestion of Tönnis ≥2 change)? [1]
• Is a single-stage option realistic, or is the trade-off of a two-stage cell procedure justified? [1]
• What is the realistic activity target at 6 months and 12 months, accepting that high-impact sport is not guaranteed? [7]

Service information (London)

London Cartilage Clinic (Harley Street), within the wider MSK Doctors group, provides joint-preservation assessment and surgical planning for knee AMIC and hip cartilage strategies; Professor Paul Lee is among the surgeons involved in cartilage restoration discussions.

1. [1] Rehabilitation of the Knee After Autologous Matrix-Induced Chondrogenesis: A Systematic Review of Rehabilitation Protocols and Clinical and Radiological Outcomes. (2025). https://doi.org/10.1177/23259671251391794 https://doi.org/10.1177/23259671251391794
2. [2] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, microfragmented adipose tissue transplantation (MATT) and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029
3. [3] Comparison of Three Different Techniques for the Treatment of Cartilage Lesions—Matrix-Induced Autologous Chondrocyte Implantation (MACI) Versus Autologous Matrix-Induced Chondrogenesis (AMIC) and Arthroscopic Minced Cartilage—A 2-Year Follow-Up on Patient-Reported Pain and Functional Outcomes. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194